HCPLive

Low Muscle Strength, Cardiorespiratory Fitness Worsens Insulin Resistance in Teens

THURSDAY, April 25 (HealthDay News) -- Lower levels of abdominal muscle strength and cardiorespiratory fitness (CRF) in youth are independently associated with adverse levels of fasting insulin, insulin sensitivity, and β-cell function in young adulthood, according to a study published online April 11 in Diabetes Care.

Anders Grøntved, MPH, from the University of Southern Denmark, in Odense, and colleagues analyzed data from 317 youth prospectively followed for 12 years. The participants had measurements taken in youth for maximal voluntary contractions during isometric back extension and abdominal flexion using a strain-gauge dynamometer, while CRF was obtained from a maximal cycle ergometer test. Additionally, fasting serum insulin and glucose were measured during youth and in young adulthood.

The researchers found that for each one standard deviation difference in isometric muscle strength (0.16 N/kg) in youth, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and HOMA of β-cell function (HOMA-B) in young adulthood changed by −11.3, −12.2, and −8.9 percent, respectively, in young adulthood. These findings were after adjusting for CRF, personal lifestyle, and demographic factors. Results were consistent even with additional adjustment for general or abdominal adiposity in youth. There was an additive combined association between muscle strength and CRF with fasting insulin, HOMA-IR, and HOMA-B. Adolescents in the highest sex-specific tertile for both isometric muscle strength and CRF had the lowest levels of these glucose metabolism outcomes.

"Increasing muscle strength and CRF should be targets in youth primordial prevention strategies of insulin resistance and β-cell dysfunction," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

The US Food and Drug Administration (FDA) on Thursday approved Orkambi (lumacaftor/ivacaftor/Vertex) to treat cystic fibrosis patients age 12 and older with two copies of the F508del mutation in the CFTR gene.
Researchers from the University of California-Santa Barbara recently announced they have created an implantable “artificial pancreas” that could potentially eliminate the need for insulin injections and pumps for treating type 1 diabetes.
As more research is done the more it appears brown fat will play a key role in the future treatment of diabetes.
Weighing the pros and cons of prescription opioid use for chronic pain is an ongoing battle, and new research may have just added to the list of disadvantages.
$vAR$